CAMBRIDGE, Mass., Jan. 6, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its CEO, Robert J. Gould, will present at the 32nd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Thursday, January 16, 2014 at 12 p.m. PST and a live webcast will be available at this link or by visiting the Investor Center on www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
SOURCE Epizyme, Inc.